AG
NVLN

Artal Group’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Artal Group’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-256,400
Closed -$315K – 136
2019
Q1 		$315K Hold
256,400
– – 0.02% 103
2018
Q4 		$215K Hold
256,400
– – 0.01% 104
2018
Q3 		$759K Hold
256,400
– – 0.03% 103
2018
Q2 		$944K Hold
256,400
– – 0.02% 98
2018
Q1 		$897K Hold
256,400
– – 0.01% 106
2017
Q4 		$800K Hold
256,400
– – 0.01% 116
2017
Q3 		$1.8M Hold
256,400
– – 0.04% 97
2017
Q2 		$2.37M Hold
256,400
– – 0.05% 91
2017
Q1 		$2.75M Hold
256,400
– – 0.07% 76
2016
Q4 		$2.16M Buy
+256,400
New +$2.27M 0.06% 77

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $38.5M AUM 24.72% 1-Year Est. Return
HCM
Highbridge Capital Management New York $1.58B AUM 31.19% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $114M AUM 77.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return
DMK
David M. Knott $264M AUM 59.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $3.03B AUM 104.56% 1-Year Est. Return
FSA
Franklin Street Advisors Chapel Hill, North Carolina $1.79B AUM 28.1% 1-Year Est. Return